Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective
Overall, the model predicts that the introduction of SOC + MMBV has the potential to be cost-saving and promote antimicrobial stewardship for both adult and paediatric CAP patients.
Authors
- Daniela Afonso (ORCID: https://orcid.org/0000-0002-0389-7912)
- Deborah J. Watkins (ORCID: https://orcid.org/0000-0002-6692-2206)
- Monica Garrett (ORCID: https://orcid.org/0000-0002-5802-3198)
- Enitan D. Carrol (ORCID: https://orcid.org/0000-0001-8357-7726)
- Sara Graziadio
- Jonathan Cooke (ORCID: https://orcid.org/0000-0001-5016-9048)
- Tim Felton (ORCID: https://orcid.org/0000-0001-6868-6633)
- William Green (ORCID: https://orcid.org/0000-0002-9004-1951)
- Emily Gregg (ORCID: https://orcid.org/0009-0003-2969-793X)
- K. Watts
Institutions
- University of Liverpool (GB)
- Leeds and York Partnership NHS Foundation Trust (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- Alder Hey Children's NHS Foundation Trust (GB)
- NIHR Leeds In Vitro Diagnostics Co-operative (GB)
- Wythenshawe Hospital (GB)
- Imperial College London (GB)
- University of York (GB)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1093/jacamr/dlaf016
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.77